Chronic cough and an atypical peripheral pattern on chest imaging: A case report secondary to suspected drug onset.

CONCLUSION: To our knowledge, this is the first case of asthma and CEP in a patient taking adalimumab (a TNF-inhibitor). Our patient likely had eosinophilic asthma phenotype, which works through the Th2 cell pathway. His psoriasis, which is primarily a Th1 cell pathway disease, likely masked his asthma most of his life. Once on adalimumab, the Th1 response was suppressed and the Th2 pathway was unmasked-revealing itself clinically as asthma. The events that led to the diagnosis of asthma were unknown. However, his symptoms began after starting adalimumab and may explain the chronic pulmonary changes and the possibility that this drug indirectly caused CEP. PMID: 28402696 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research